Monoclonal antibodies (mAB) are increasingly growing in importance for the diagnosis and therapy of various diseases, including cancer as well as autoimmune and inflammatory disorders. One essential parameter to define their quality is the content of aggregates (dimers, trimers and higher aggregates). These aggregates can be formed during processing and purification or are the result of long-term storage. Due to the aggregation antibodies lose their pharmaceutical efficacy and can facilitate an immune response.
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE!
